| Document |
Document Title |
|
WO/2022/211631A1 |
A continuous method for depolymerizing polycaprolactam waste into caprolactam is described. In the method, a melt of the polycaprolactam waste and an inert gas are fed to a reactor in a continuous manner. Water and an aromatic hydrocarbo...
|
|
WO/2021/257696A9 |
Compounds and methods are provided for inhibiting an aldehyde dehydrogenase (ALDH). Methods of treating cancer are also provided. The ALDH-inhibitor can be a compound that is based on a cyclic guanidine, or an imidazolium core. In certai...
|
|
WO/2022/196043A1 |
The present invention further improves the selectivity of ε-caprolactam. This method is for producing zeolite and comprises steps (1)-(5). Step (1): A step for mixing tetraalkyl orthosilicate, water, and a hydroxylated quaternary am...
|
|
WO/2022/189911A1 |
Method for the preparation of amidines or their derivatives, comprising the following steps: - synthesis of nitrile lactams by reaction between a lactam and an α-β unsaturated nitrile; - synthesis of N-(aminoalkyl) lactams by reducing ...
|
|
WO/2022/185227A1 |
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatmen...
|
|
WO/2022/184172A1 |
A benzazepine fused ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/156449A1 |
The present invention relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and pharmaceutically acceptab...
|
|
WO/2022/152097A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/155037A1 |
Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y'...
|
|
WO/2022/111581A1 |
A benzazepine spiro derivative as represented by formula (I) and a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and/or treatment of diseases related to vasopressin receptors.
|
|
WO/2022/090138A1 |
The present invention relates to new processes for the preparation of known polymorphs of ivabradine HCl, said processes being characterized by robust protocols suitable for industrial production.
|
|
WO/2022/060811A1 |
In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3...
|
|
WO/2022/036080A1 |
The present disclosure relates to compounds of Formula (I) and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/025117A1 |
The present invention provides the compound represented in general formula (A1) [Ar1 is a C6-14 aryl group or a C5-14 nitrogen-containing heteroaryl group, substituted with at least two electron-attracting groups; R1 is a C1-30 alkyl gro...
|
|
WO/2022/014397A1 |
This refining method is for crystallizing a compound having at least one crystal form. A specific infrared wavelength and a specific concentration at which a specific crystal form precipitates from a solution in which the compound is dis...
|
|
WO/2022/014396A1 |
A purification method according to the present invention is a purification method that brings about the crystallization of a compound that has at least one crystalline form. A prescribed infrared wavelength and prescribed temperature at ...
|
|
WO/2021/249877A1 |
The present invention relates to new intermediates for the synthesis of Tolvaptan and of its derivatives and a process for its preparation involving said intermediates.
|
|
WO/2021/226440A1 |
The invention provides immunoconjugates of Formula I comprising a cell-binding agent linked by conjugation to one or more immunostimulatory moieties where the linker is a substrate for elastase. The invention also provides immunostimulan...
|
|
WO/2021/214727A1 |
Cancer stem cells are responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. There exists an urgent need to identify new mitochondrial inhibitor drugs that can target and eradic...
|
|
WO/2021/208945A1 |
Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable sal...
|
|
WO/2021/208201A1 |
The present invention provides an external micro-interface ammoximation reaction system and method. The external micro-interface ammoximation reaction system comprises an oximation reactor, a reaction clear liquid buffer tank, a tert-but...
|
|
WO/2021/208918A1 |
Provided are a class of compounds, represented by formula (I"'), as selective EGFR inhibitors, a pharmaceutical composition containing the compounds, useful intermediates for preparing the compounds, and a method for using the compounds ...
|
|
WO/2021/208200A1 |
The present invention provides a built-in micro-interface ammoximation reaction system and method, the system comprising an oximation reactor, a reaction supernatant buffer tank, a tert-butanol recovery tower, an extraction tank, a water...
|
|
WO/2021/188620A1 |
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sa...
|
|
WO/2021/182803A1 |
The present invention relates to a novel oxidized lappaconitine derivative and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a medical use thereof using osteogenesis-promoting activity. The lappaconitine ...
|
|
WO/2021/182806A2 |
The present invention pertains to a novel lappaconitine derivative, a method for producing same, and a pharmaceutical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cel...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
|
WO/2021/157642A1 |
The present invention improves the light emission efficiency, driving voltage, and lifespan of an organic electroluminescent element using a delayed fluorescent material. A host material for a delayed fluorescent material and comprising ...
|
|
WO/2021/157593A1 |
Superior durability is demonstrated by an organic light emitting element that uses a light emitting composition including both a first compound with a PBHT value greater than 0.730 and a second compound for which ES1 is smaller than for ...
|
|
WO/2021/147398A1 |
A preparation method for a chiral oxoazacycloalkane compound as shown in formula (I), comprising the steps of: using a compound as shown in formula (II) of R or S as a raw material, performing a cyclization reaction under the action of a...
|
|
WO/2021/138314A1 |
The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used for the treatment, prevention, diagnosis and/or management of vario...
|
|
WO/2021/122249A1 |
Process to produce N-vinyl compounds by homogeneous catalysis, wherein acetylene is reacted with a cyclic compound comprising a cyclic compound having at least one nitrogen as ring member, bearing a substitutable hydrogen residue (cyclic...
|
|
WO/2021/122955A1 |
The invention concerns a method for preparing a mixture containing cyclohexanol and cyclohexanone, comprising the step of hydrogenating cyclohexyl hydroperoxide in cyclohexane in the presence of a Raney nickel catalyst to give cyclohexan...
|
|
WO/2021/119004A1 |
A process for the synthesis of N-alkylated lactams via reductive alkylation. The process of the present disclosure may be conducted by the addition of an aldehyde to a lactam in the presence of a catalyst under a reducing atmosphere.
|
|
WO/2021/098859A1 |
An aza seven-membered ring inhibitor, and a preparation method therefor and use thereof. Specifically, a compound has a structure represented by formula (I). Disclosed are a preparation method for the compound and the use of same as a KR...
|
|
WO/2021/099244A1 |
The invention aims to improve the oxidizing and bleaching properties of peroxygen compounds at low temperatures. These properties can be improved by essentially using compounds that form organic peroxoacids having a cationic group under ...
|
|
WO/2021/094184A1 |
The invention provides a process and a plant for the production of ε-caprolactam and crystalline ammonium sulfate in an industrial-scale plant, wherein the plant comprises a Beckmann rearrangement reaction section, an ammonium sulfate c...
|
|
WO/2021/085636A1 |
[Problem] To provide a novel means capable of generating highly stereoselective and/or highly efficient amidation reactions in a variety of substrates having a carboxyl group and an amino group, and capable of producing amide compounds. ...
|
|
WO/2021/073231A1 |
The present invention relates to the field of chemical and pharmaceutical preparation, and in particular, to a preparation method for eslicarbazepine. The method is obtained by reacting oxcarbazepine in the presence of a chiral catalyst ...
|
|
WO/2021/067242A1 |
The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more 8-amido-2-aminobenzazepine derivatives. The invention also provides 8-amido-2-aminobenzazepine derivative intermediate compo...
|
|
WO/2021/018298A1 |
Disclosed is a class of indolo-seven-membered acyloxime compounds, and specifically disclosed are compounds as shown in formula (I), and pharmaceutically acceptable salts thereof.
|
|
WO/2020/252254A1 |
The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivati...
|
|
WO/2020/252294A1 |
The application relates to immunoconjugates of Formula (I) comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of F...
|
|
WO/2020/249759A1 |
The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.
|
|
WO/2020/245213A1 |
The present invention relates to tricyclic derivatives of formula (I), which are useful as inhibitors of HECT-domain-containing E3 ligases, in particular NEDD4. The present invention also refers to pharmaceutical compositions comprising ...
|
|
WO/2020/242315A1 |
The invention relates to the field of antimicrobial materials, in particular to implantable and other medical devices, exhibiting antimicrobial activity. Provided is a method for providing a substrate with an antimicrobial coating compri...
|
|
WO/2020/238917A1 |
The present invention relates to a tetrahydro-1H-benzazepine compound as potassium channel modulator, a preparation method and a use thereof. Specifically, the compound of the present invention has the structure shown by formula A, where...
|
